Loading stock data…
OmniAb (OABI)
$4.24-0.09 (-2.08%)
Market ClosedLast close Sep 8
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OmniAb, Inc. in the Healthcare sector is trading at $4.24 with a market capitalization of $302M. Wall Street consensus targets $8.40 (5 analysts), implying a +98.1% move over the next 12 months. The stock is currently 22% below its 52-week high of $5.43, remaining 94.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +98.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.43M↑ | $8.38M↑ | $2.24M↓ | $3.90M↓ | $4.15M |
| Gross Profit | $14.41M↑ | $8.37M↑ | $2.21M↓ | $3.63M↓ | $4.15M |
| Operating Income | -$7.83M↑ | -$15.77M↑ | -$18.14M↑ | -$19.22M↓ | -$18.84M |
| Net Income | -$7.71M↑ | -$14.18M↑ | -$16.52M↓ | -$15.88M↑ | -$18.20M |
Peer Comparison
JNJUNHPFE
Fundamentals
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$301.54M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.67%
Volume
Today's trading volume
1.27M
Recent News
Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?
On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics. Leveraging OmniAb’s specialized antibody discovery platform, the deal grants Lilly exclusive global rights to commercialize resulting candidates in exchange for an upfront payment, up to $370 million in […]
Why Eli Lilly (LLY) Stock Is Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company acquired rights to a preclinical Alzheimer's drug and entered a collaboration for an ion channel program.
Eli Lilly (LLY) Adds Neuroscience And Lung Cancer Research Deals
Eli Lilly (NYSE: LLY) announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer. The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline. The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients. These deals expand Eli Lilly's external R&D partnerships...
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook
Licensing activity strengthens the biotech's balance sheet.
Top Midday Gainers
OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery progra